Gelmon, K.A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., et al. (2011) Olaparib in Patients with Recurrent High-Grade Serous or Poorly Differentiated Ovarian Carcinoma or Triple-Negative Breast Cancer A Phase 2, Multicentre, Open-Label, Non-Randomised Study. The Lancet Oncology, 12, 852-861. - References

Browse Menu >>

Browse Subjects >>

Computer Science & Communications

Earth & Environmental Sciences

Social Sciences & Humanities

Why Us? >>

- Open Access
- Peer-reviewed
- Rapid publication
- Lifetime hosting
- Free indexing service
- Free promotion service
- More citations
- Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

Contact Us >>

customer@scirp.org

+86 18163351462(WhatsApp)

1655362766

Paper Publishing WeChat

Book Publishing WeChat

(or Email:book@scirp.org)

Article citations
More>>

Gelmon, K.A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., et al. (2011) Olaparib in Patients with Recurrent High-Grade Serous or Poorly Differentiated Ovarian Carcinoma or Triple-Negative Breast Cancer: A Phase 2, Multicentre, Open-Label, Non-Randomised Study. The Lancet Oncology, 12, 852-861. http://dx.doi.org/10.1016/S1470-2045(11)70214-5

has been cited by the following article:

TITLE: Current Possible Drug Therapies for Ovarian Cancer

AUTHORS: Jungyeob Seoung, Young-Han Park, Chaechun Rhim, Sungju Kim

KEYWORDS: Ovarian Cancer, Intraperitoneal Chemotherapy, Targeting Therapy

JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.13, November 7, 2014

ABSTRACT: Ovarian cancer is the most aggressive gynecologic cancer of the heterogenous phenotypes. Development of the new chemotherapeutic agents and drug delivery mode makes better outcomes for patient treatments. Optimal cytoreductive therapy followed by molecular targeting therapy, intraperitoneal chemotherapy and dose dense chemotherapy is a hot therapeutic concept in ovarian cancers. In our review, we will introduce recent therapeutic advances in epithelial ovarian cancer patients.

Open Access

Clinicopathological and Immunohistochemical Features of Triple Negative Breast Cancer

Heng Chen, Jinjun Li, Wei Tan

DOI: 10.4236/abcr.2017.64008 1,045 Downloads 2,533 Views Citations

Pub. Date: September 8, 2017

Open Access

Cytotoxicity Study of Gold Nanoparticles on the Basal-Like Triple-Negative HCC-1937 Breast Cancer Cell Line

Christophe Massard, Clémence Dubois, Vincent Raspal, Pierre Daumar, Yves Sibaud, Emmanuelle Mounetou, Mahchid Bamdad, Oscar Komla Awitor

DOI: 10.4236/jbnb.2018.91002 757 Downloads 1,412 Views Citations

Pub. Date: December 18, 2017

Open Access

Efficacy Study of Metronomic Chemotherapy in Metastatic Triple Negative Breast Cancer and Correlation with VEGF, TSP Levels

B. J. Srinivasa, Lalkota Prakash Bhanu, Vidhya H. Veldore, R. Raghavendra, Radheshyam Naik

DOI: 10.4236/abcr.2018.72007 680 Downloads 1,384 Views Citations

Pub. Date: April 13, 2018

Open Access

Treatment Patterns and Mortality Risk among Elderly Patients with Metastatic Triple Negative Breast Cancer in the United States: An Observational Cohort Study Using SEER-Medicare Data

Sacha Satram-Hoang, Preeti Bajaj, Alisha Stein, Patricia Cortazar, Faiyaz Momin, Carolina Reyes

DOI: 10.4236/jct.2019.102009 643 Downloads 1,100 Views Citations

Pub. Date: February 15, 2019

Open Access

Clinicopathological Characteristics of Basal Type Breast Cancer in Triple-Negative Breast Cancer

Goro Kutomi, Tousei Ohmura, Yasuyo Suzuki, Hidekazu Kameshima, Hiroaki Shima, Tomoko Takamaru, Fukino Satomi, Seiko Otokozawa, Mitsuru Mori, Koichi Hirata

DOI: 10.4236/jct.2012.325106 6,414 Downloads 14,752 Views Citations

Pub. Date: November 2, 2012

Follow SCIRP